# Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In

Source: https://onco.cc/trials/nct07742956/  
OnCo record `nct07742956` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Shanghai Allink Biotherapeutics Co., Ltd., not yet recruiting.

## Summary

Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. is a phase 2, randomised interventional study registered as NCT07742956 by Shanghai Allink Biotherapeutics Co., Ltd., with a registry enrolment figure of 156 participants, started 2026-08-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: ALK201 for injection; Ivonescimab Injection. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: TEAEs. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07742956
- Phase: 2
- Setting: An Open-label, Multicenter Phase II Clinical Trial to Evaluate ALK201 for Injection Combined With Ivonescimab Injection in Subjects With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT07742956: https://clinicaltrials.gov/study/NCT07742956

## Connected records

- cancers: [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07742956.json